EVOLVA N Logo
CH0021218067
A0EAKH
EVE.SW

EVOLVA N

Cargando cotizaciones...

Previsión

No hay datos de analistas disponibles para esta empresa.


  • Evolv expands partnership with Gillette Stadium and becomes official provider for fan security screening

    Evolv has renewed and expanded its partnership with Gillette Stadium, which began in 2021, so that KI-supported Evolv Express security lanes will be installed at additional entrances. The systems are designed to detect concealed weapons at normal walking speed and have already screened more than seven million visitors at the stadium. The contract extension strengthens Evolv’s presence in the greater Boston area; the company reports 36.6% revenue growth last year, Q2 revenue of $32.5 million (+29%) and remains unprofitable despite strong demand (negative EBITDA). Analyst reactions raised price targets and ratings but highlighted the still-present valuation premium. » Más en de.investing.com


  • Evolv Technologies reaches new 52-week high at $7.45

    Shares of Evolv Technologies Holdings Inc. rose to a new 52-week high of $7.45 after the stock gained about 143.77% over the past year. The company reported revenue growth of 36.71%, a positive EBITDA in the first quarter, a $75 million credit facility from MidCap Financial and a $19.36 million school contract with Gwinnett Schools; analyst price targets range from $5.50 to $8.25. Positive analyst revisions (Northland, Craig-Hallum, Lake Street) and the resolution of an FTC probe are cited as drivers of the optimistic sentiment. » Más en de.investing.com


  • Evolv Technologies reaches new 52-week high after strong growth and positive analyst ratings

    Evolv Technologies' stock climbed to a 52-week high of $7.10, supported by revenue growth of 36.71% and strong performance over the past year. The company also secured a $75 million credit facility to strengthen its subscription-based business and significantly exceeded revenue expectations in the first quarter. Analysts upgraded the stock to 'Outperform' or 'Buy' due to improved financial metrics and strategic initiatives. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, EVOLVA N tuvo unos ingresos de 0,00 y un beneficio neto de 313,08k
(EUR) dic 2025
YoY
Ingresos 0,00 -
Beneficio bruto 0,00 -
Beneficio neto 313,08k -
EBITDA 0,00 -

Datos fundamentales

Métrica Valor
Capitalización bursátil
+18,16M
Número de acciones
7,21M
Máximo/mínimo de 52 semanas
+21,96 - +0,66
Dividendos No
Beta
-0,05
Ratio P/E
26,44
Ratio PEG
+0,12
Ratio P/B
+2,90
Ratio P/S
0,00

Perfil de la empresa

Evolva Holding SA entdeckt, erforscht, entwickelt und vermarktet Inhaltsstoffe auf natürlicher Basis, die in der Schweiz, in den Vereinigten Staaten und international in den Bereichen Aromen und Düfte, gesundheitliche Inhaltsstoffe, Gesundheitsschutz und in anderen Sektoren verwendet werden. Das Unternehmen bietet verschiedene Inhaltsstoffe an, darunter Veri-te Resveratrol, ein natürliches Polyphenol, das in Weintrauben und anderen Pflanzen, einschließlich Erdnüssen, Cranberries und Beeren, vorkommt; L-Arabinose, ein Aromastoff, der bei der Maillard-Reaktion verwendet wird; Valencen, ein Aromabestandteil von Zitrusfrüchten und aus Zitrusfrüchten gewonnenen Duftstoffen; Nootkaton, ein Aromabestandteil von Grapefruit, der durch biochemische Oxidation von Valencen gewonnen wird; und Vanillin, ein Hauptbestandteil von Vanilleschotenextrakt. Das Unternehmen wurde 2004 gegründet und hat seinen Hauptsitz in Reinach, Schweiz.

Nombre
EVOLVA N
CEO
Gerhard Lobmaier
Sede Reinach, bl
Suiza
Sitio web
Salida a bolsa
03/05/2005
Empleados 49

Símbolos bursátiles

Bolsa Símbolo
SIX
EVE.SW
Frankfurt
ADF.F
London
0QQJ.L
München
ADF.MU
🍪

Parqet  usa cookies. Más información